A new eye drop therapy offers a non-invasive alternative for treating dry age-related macular degeneration. Massively ...

Korean scientists have developed a revolutionary eye drop treatment for dry age-related macular degeneration (AMD), potentially eliminating the need for regular eye injections that millions of elderly ...

D Molecular Therapeutics reaches agreement with FDA for phase 3 trial design of DME candidate 4D-150, showing promising ...

Toll-like receptors (TLRs) are vital components of the immune system, acting as sentinels that detect and respond to ...

Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level3E10 vg/eye demonstrated strong signals of clinical ...

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Age related macular degeneration (AMD) is the leading cause of vision loss in individuals over 65, characterized by abnormal changes in the macular, resulting in reduced vision and ...

Opens in a new tab or window Obstructive sleep apnea (OSA) was linked to a more than twofold risk of developing age-related macular degeneration ... to require anti-VEGF injections to treat ...

Age-related macular degeneration also requires a dilated eye exam to be diagnosed and is ... The new options, administered as injections, are not suitable for everyone with dry AMD, but Rosdahl ...

Pravin U. Dugel, MD, Ocular's Executive Chairman, President and CEO, will provide an update regarding the enrollment status ...

Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 ...